---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010758"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:39:57.032329+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics Q4 2022 net loss $5.1M; cash runway extended into Q2 2024

## Summary
- Net loss of $5.1M for Q4 2022 vs net income of $1.6M in Q4 2021; full-year net loss $18.8M vs $36.1M in 2021.
- Cash and cash equivalents $70.1M as of Dec 31, 2022; expects runway into Q2 2024.
- Phase 3 prostate cancer trial topline data expected Q4 2024; phase 2 NSCLC data expected Q3 2023.
- Paused enrollment in phase 2 pancreatic cancer trial subject to additional funding; initial data still expected Q4 2023.
- CAN-3110 in recurrent HGG showed median overall survival of 11.6 months in phase 1 trial.

## SEC filing metadata
- accession: 0000950170-23-010758
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/0000950170-23-010758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/cadl-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010758
- JSON: https://secwatch.observer/filing/0000950170-23-010758.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010758.txt

## Key facts
- Earnings Releases
  Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/0000950170-23-010758-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.